Alector, Inc. — Form 10-Q
Filed November 5, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 78/100
What the filing says
Alector granted Genentech exclusive worldwide rights to develop and commercialize AL050, an engineered glucocerebrosidase enzyme replacement therapy for Parkinson's disease and neurodegeneration. Alector receives $100 million upfront payment, up to $1.17 billion in development/regulatory/commercial milestone payments, and tiered royalties on net sales. Genentech assumes all development, manufacturing, and commercialization responsibility; Alector retains ownership of its proprietary Alector Brain Carrier platform for use in its own pipeline.
Why this rating
Material deal for $115M company: $100M upfront equals 87% of market cap, plus $1.17B milestones; transforms cash runway to 2029 per press release. Significant but not transformational—retains platform IP, validates asset value.
Tradability signal
NO TRADE
No trade: positive news with only -1.9% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.53% over 4 hrs, n=382). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $2.16 ▼ 0.92% | at our read · unknown $2.18 | +10 min · unknown $2.15 ▼ 1.38% | +30 min · unknown $2.21 ▲ 1.38% | +1 hr · unknown $2.19 ▲ 0.69% | +4 hrs · unknown $2.28 ▲ 4.54% |
The stock had already moved +0.93% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.